相关实验视频

Updated: Jun 26, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

CYP2C19多态和冠状动脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静

Yusra Pintaningrum¹, Vitriyaturrida², Ivana Purnama Dewi^3,4

¹Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Mataram, Mataram, West Nusa Tenggara, 83126, Indonesia.

|May 9, 2024

概括

患有CYP2C19功能丧失 (LOF) 基因的患者在冠状动脉支架后存在明显更高的内置支架置症 (ISR) 风险. 这一发现突显了遗传因素在预测用克洛皮多格雷尔治疗患者的ISR结果方面的重要性.

科学领域:

心脏病学心脏病学
药物基因组学药物基因组学
遗传学遗传学是一个

背景情况:

静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉
关于CYP2C19功能丧失 (LOF) 基因变异与ISR患病率之间的联系仍在争论中.
之前的研究已经产生了相互矛盾的结果,通常是由于样本大小小小.

研究的目的:

系统地审查和对现有研究进行元分析.
为了确定CYP2C19 LOF基因型和ISR患病率之间的关联.
为了更好地理解这种药物遗传关系.

主要方法:

进行了全面的文献搜索,截至2021年4月.
静脉静脉缩 (ISR) 是主要的结局,使用 95% 置信区间 (CI) 的几率比率 (OR) 进行评估.
研究质量使用纽卡斯尔-太华尺度进行评估,异质性使用I2统计数据进行评估.

主要成果:

分析包括四项非随机对照试验,共284名患者.
与野生型基因型 (n=206) 患者相比,患有CYP2C19 LOF基因型 (n=78) 的患者患有ISR的风险更高.
洛夫基因型与ISR风险增加显著相关 (或95% CI = 2.71 [1.42-5.16],P = 0.003).

结论:

携带CYP2C19 LOF等位基因的患者患上ISR冠状动脉后支架的可能性较高.
这种增加的风险在用克洛皮多格雷尔治疗的患者中尤其明显.
这些发现的临床应用需要考虑研究特定的变异性.

关键词:

在CYP2C19中.克洛皮多格雷尔的使用方法冠状动脉静脉静脉静脉静脉静脉静脉静脉静脉静脉静脉多形态主义的多态主义.系统性审查系统性审查

更多相关视频

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

相关概念视频

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...